Inventor · disambiguated record
Marie-Lise Gougeon
Also filed as: GOUGEON MARIE-LISE
14 granted patents·5 pending applications·38 citations·filing 2009–2024
90Inventor score
Files withPASTEUR INSTITUT10GOUGEON MARIE-LISE3INST NAT SANTE RECH MED3CENTRE NAT RECH SCIENT2PERFETTINI JEAN-LUC1
Top patents by PatentIndex Score
19 records- 0188US8906634B2Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistencePASTEUR INSTITUT·Filed 2013·Granted Dec 9, 2014·10 cites·20 claims
- 0285US9164107B2HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disordersPASTEUR INSTITUT·Filed 2014·Granted Oct 20, 2015·4 cites·20 claims
- 0384US9766254B2HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disordersPASTEUR INSTITUT·Filed 2015·Granted Sep 19, 2017·2 cites·19 claims
- 0483US8450076B2Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistenceGOUGEON MARIE-LISE·Filed 2009·Granted May 28, 2013·6 cites·24 claims
- 0581US9164103B2Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistencePASTEUR INSTITUT·Filed 2013·Granted Oct 20, 2015·4 cites·19 claims
- 0681US8603766B2Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistenceGOUGEON MARIE-LISE·Filed 2009·Granted Dec 10, 2013·5 cites·17 claims
- 0776US10012655B2Method for quantitating total HMGB1 protein in biological samplesPASTEUR INSTITUT·Filed 2014·Granted Jul 3, 2018·2 cites·21 claims
- 0875US2024398981A1Novel nanoparticles of antiretroviral drugs, their preparation and their use for the treatment of viral infectionsCENTRE NAT RECH SCIENT·Filed 2024·Application pending·0 cites
- 0969US12105095B2Assay to detect and quantitate specific antibodies for various redox forms of HMGB1PASTEUR INSTITUT·Filed 2022·Granted Oct 1, 2024·0 cites·6 claims
- 1069US8728748B2HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disordersGOUGEON MARIE-LISE·Filed 2011·Granted May 20, 2014·4 cites·25 claims
- 1164US2022008554A1Novel nanoparticles of antiretroviral drugs, their preparation and their use for the treatment of viral infectionsCENTRE NAT RECH SCIENT·Filed 2019·Application pending·0 cites
- 1263US9547006B2Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planusPASTEUR INSTITUT·Filed 2014·Granted Jan 17, 2017·1 cites·8 claims
- 1359US10018629B2Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planusPASTEUR INSTITUT·Filed 2014·Granted Jul 10, 2018·0 cites·9 claims
- 1456US11460473B2Assay to detect and quantitate specific an antibodies for various redox forms of HMGB1PASTEUR INSTITUT·Filed 2016·Granted Oct 4, 2022·0 cites·10 claims
- 1552US2020297749A1Methods and Pharmaceutical Composition for Modulation Polarization and Activation of MacrophagesINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 1649US2018125876A1Methods and Pharmaceutical Composition for Modulation Polarization and Activation of MacrophagesINST NAT SANTE RECH MED·Filed 2016·Application pending·0 cites
- 1748US9938528B2Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infectionsINST NAT SANTE RECH MED·Filed 2015·Granted Apr 10, 2018·0 cites·19 claims
- 1842US2013156791A1Methods and pharmaceutical compositions for the treatment of hiv-1 infectionsPERFETTINI JEAN-LUC·Filed 2011·Application pending·0 cites
- 1929US10890583B2Predictive value of Clostridium difficile-specific immune response for recurrence and disease outcomePASTEUR INSTITUT·Filed 2015·Granted Jan 12, 2021·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Marie-Lise Gougeon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →